Patents by Inventor John A. Beutler
John A. Beutler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11098054Abstract: Disclosed is a compound of formula (I) in which a, R1-R5 and X1 are as described herein. Also disclosed are a pharmaceutical composition containing the compound and a method of using the compound for treating cancer, such as renal cancer.Type: GrantFiled: July 5, 2018Date of Patent: August 24, 2021Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Sciences, Fundacio Institut Catala D'Investigacio Quimica, University of Delaware, University of Leeds, Universitat Rovira I VirgiliInventors: John A. Beutler, Antonio Echavarren, William Chain, David Beech, Zhenhua Wu, Jean-Simon Suppo, Fernando Bravo, Hussein Rubaiy
-
Publication number: 20200140451Abstract: Disclosed is a compound of formula (I) in which a, R1-R5 and X1 are as described herein. Also disclosed are a pharmaceutical composition containing the compound and a method of using the compound for treating cancer, such as renal cancer.Type: ApplicationFiled: July 5, 2018Publication date: May 7, 2020Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, Fundacio Institut Catala D'Investigacio Quimica, University of Delaware, University of Leeds, Universitat Rovira I VirgiliInventors: John A. Beutler, Antonio Echavarren, William Chain, David Beech, Zhenhua Wu, Jean-Simon Suppo, Fernando Bravo, Hussein Rubaiy
-
Patent number: 10287297Abstract: Disclosed is a compound of formula (I) in which R1-R5 and X1 are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer and a method of treating diabetes.Type: GrantFiled: April 13, 2016Date of Patent: May 14, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Fundació Institut Català d'Investigació Quimica (ICIQ), Universitat Rovira i VirgiliInventors: John A. Beutler, Antonio M. Echavarren, Laura Lopez, Fernando Bravo, Lorena Riesgo, Tanya Tannaquil Ransom
-
Publication number: 20180127433Abstract: Disclosed is a compound of formula (I) in which R1-R5 and X1 are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer and a method of treating diabetes.Type: ApplicationFiled: April 13, 2016Publication date: May 10, 2018Applicants: The United States of America, as represented by the Secretary, Department of Health and Human, Fundació Institut Català d'Investigació Química (ICIQ), Universitat Rovira i VirgiliInventors: John A. BEUTLER, Antonio M. ECHAVARREN, Laura LOPEZ, Fernando BRAVO, Lorena RIESGO, Tanya Tannaquil RANSOM
-
Patent number: 9676788Abstract: Disclosed is a compound of formula (I) or formula (II): (Formulas should be inserted here) wherein R1-R6 are as defined herein. Also disclosed are a pharmaceutical composition comprising such a compound and a method of treating or preventing cancer in a mammal in need thereof, comprising administering to the mammal a compound of formula (I) or formula (II).Type: GrantFiled: February 5, 2015Date of Patent: June 13, 2017Assignees: The United States of America, as represented by the Secretary of Health and Human Services, University of HawaiiInventors: William J. Chain, John A. Beutler, David Fash, William D. Figg, Zhenwu Li, Cody John Peer, Joe William Ramos, Florian J. Sulzmaier
-
Patent number: 9517224Abstract: Disclosed is a method of activating protein kinase C theta (PKC?) in an HIV or HTLV infected animal comprising administering to the animal an effective amount of a compound of formula (I): Formula (I), or an epimer thereof; wherein Ar and R1-R6 are described herein. Examples of diseases or conditions associated with PKC? include HIV1 infection, AIDS, HTLV infection, and adult T cell leukemia/lymphoma.Type: GrantFiled: November 13, 2013Date of Patent: December 13, 2016Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Leonard M. Neckers, Carole Sourbier, Jane B. Neckers, Min-Jung Lee, John A. Beutler, W. Marston Linehan, Bradley T. Scroggins, Sunmin Lee
-
Publication number: 20160347764Abstract: Disclosed is a compound of formula (I) or formula (II): (Formulas should be inserted here) wherein R1-R6 are as defined herein. Also disclosed are a pharmaceutical composition comprising such a compound and a method of treating or preventing cancer in a mammal in need thereof, comprising administering to the mammal a compound of formula (I) or formula (II).Type: ApplicationFiled: February 5, 2015Publication date: December 1, 2016Applicants: The United State of America, as represented by the Secretary, Department of Health and Human Service, University of HawaiiInventors: William J. Chain, John A. Beutler, David Fash, William D. Figg, Zhenwu Li, Cody John Peer, Joe William Ramos, Florian J. Sulzmaier
-
Publication number: 20150283111Abstract: Disclosed is a method of activating protein kinase C theta (PKC?) in an HIV or HTLV infected animal comprising administering to the animal an effective amount of a compound of formula (I): Formula (I), or an epimer thereof; wherein Ar and R1-R6 are described herein. Examples of diseases or conditions associated with PKC? include HIV1 infection, AIDS, HTLV infection, and adult T cell leukemia/lymphoma.Type: ApplicationFiled: November 13, 2013Publication date: October 8, 2015Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Leonard M. Neckers, Carole Sourbier, Jane B. Neckers, Min-Jung Lee, John A. Beutler, W. Marston Linehan, Bradley T. Scroggins, Sunmin Lee
-
Patent number: 9101601Abstract: Disclosed are methods of treating an animal for insulin resistance and associated diseases or conditions, activating the transcriptional activity of heat shock factor 1 (HSF1), or inducing the expression of heat shock protein 70 (HSP70) in an animal in need thereof, wherein the methods involve administering an effective amount of one or more compounds of formula (I) or an epimer thereof, wherein Ar, and R1-R6 are described herein. Examples of diseases or conditions associated with insulin resistance include diabetes, obesity, inflammation, metabolic syndrome, polycystic ovary disease, arteriosclerosis, non-alcoholic fatty liver disease, reproductive abnormality in a female, and growth abnormality.Type: GrantFiled: January 3, 2013Date of Patent: August 11, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Leonard M. Neckers, Carole A.C. Sourbier, W. Marston Linehan, Jane B. Neckers, Min-Jung Lee, Bradley T. Scroggins, John A. Beutler
-
Patent number: 8993768Abstract: Disclosed are compounds that inhibit RNase H activity of retroviruses, for example, a compound of formula (I) wherein R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment or prevention of infection by human immunodeficiency virus (HIV).Type: GrantFiled: May 10, 2012Date of Patent: March 31, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: John A. Beutler, Stuart F. J. LeGrice, Craig Thomas, Jian-Kang Jiang, Suhman Chung, Jennifer Wilson
-
Publication number: 20140350093Abstract: Disclosed are methods of treating an animal for insulin resistance and associated diseases or conditions, activating the transcriptional activity of heat shock factor 1 (HSF1), or inducing the expression of heat shock protein 70 (HSP70) in an animal in need thereof, wherein the methods involve administering an effective amount of one or more compounds of formula (I) or an epimer thereof, wherein Ar, and R1-R6 are described herein. Examples of diseases or conditions associated with insulin resistance include diabetes, obesity, inflammation, metabolic syndrome, polycystic ovary disease, arteriosclerosis, non-alcoholic fatty liver disease, reproductive abnormality in a female, and growth abnormality.Type: ApplicationFiled: January 3, 2013Publication date: November 27, 2014Inventors: Leonard M. Neckers, Carole A.C. Sourbier, W. Marston Linehan, Jane B. Neckers, Min-Jung Lee, Bradley T. Scroggins, John A. Beutler
-
Publication number: 20140249181Abstract: Disclosed are compounds that inhibit RNase H activity of retroviruses, for example, a compound of formula (I) wherein R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment or prevention of infection by human immunodeficiency virus (HIV).Type: ApplicationFiled: May 10, 2012Publication date: September 4, 2014Applicant: The united States of America, as represented by the Secretary, Department of Health and Human ServInventors: John A. Beutler, Stuart F.J. LeGrice, Craig Thomas, Jian-Kang Jiang, Suhman Chung, Jennifer Wilson
-
Patent number: 8686016Abstract: Disclosed is a method for preventing or treating an undesirable condition in a subject carrying cells homozygous null for the neurofibromatosis type 1 gene or subjects that are haploinsufficient for the neurofibromatosis type 1 gene, the method comprising administering to a subject in need thereof an effective amount of a schweinfurthin or schweinfurthin analog or derivative, or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Also disclosed is a new schweinfurthin compound of the formula.Type: GrantFiled: April 30, 2010Date of Patent: April 1, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Iowa Research FoundationInventors: Karlyne Reilly, Thomas Turbyville, John A. Beutler, David Wiemer
-
Patent number: 8410292Abstract: Disclosed are englerins and derivatives (I) thereof useful in the treatment of a number of cancers, particularly renal cancer, as well as pharmaceutical compositions and method of treating a patient with the use of these derivatives. The englerins, for example Englerin A and Englerin B, can be isolated from the plant Phyllanthus engleri or produced by synthetic methods. An example of the englerin derivative is 2?-chloroenglerin A, which has the structure (II), wherein double bond ‘a’ is E, Z, or a mixture of E and Z.Type: GrantFiled: December 30, 2008Date of Patent: April 2, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: John A. Beutler, Ranjala Ratnayake, David Covell, Tanya R. Johnson
-
Publication number: 20120095089Abstract: Disclosed is a method for preventing or treating an undesirable condition in a subject carrying cells homozygous null for the neurofibromatosis type 1 gene or subjects that are haploinsufficient for the neurofibromatosis type 1 gene, the method comprising administering to a subject in need thereof an effective amount of a schweinfurthin or schweinfurthin analog or derivative, or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Also disclosed is a new schweinfurthin compound of the formula.Type: ApplicationFiled: April 30, 2010Publication date: April 19, 2012Applicants: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Karlyne Reilly, Thomas Turbyville, John A. Beutler, David Wiemer
-
Publication number: 20110319481Abstract: Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.Type: ApplicationFiled: January 26, 2011Publication date: December 29, 2011Applicants: Government of the United States of America, National Institute of Health, University of Iowa Research FoundationInventors: David F. Wiemer, Jeffrey D. Neighbors, John A. Beutler
-
Patent number: 7902228Abstract: Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.Type: GrantFiled: February 4, 2008Date of Patent: March 8, 2011Assignees: University of Iowa Research Foundation, The United States of America, National Institute of HealthInventors: David F. Wiemer, Jeffrey D. Neighbors, John A. Beutler
-
Publication number: 20100286259Abstract: Disclosed are englerins and derivatives (I) thereof useful in the treatment of a number of cancers, particularly renal cancer, as well as pharmaceutical compositions and method of treating a patient with the use of these derivatives. The englerins, for example Englerin A and Englerin B, can be isolated from the plant Phyllanthus engleri or produced by synthetic methods. An example of the englerin derivative is 2?-chloroenglerin A, which has the structure (II), wherein double bond ‘a’ is E, Z, or a mixture of E and Z.Type: ApplicationFiled: December 30, 2008Publication date: November 11, 2010Applicant: The US, DHHS, NIHInventors: John A. Beutler, Ranjala Ratnayake, David Covell, Tanya R. Johnson
-
Publication number: 20080227852Abstract: Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.Type: ApplicationFiled: February 4, 2008Publication date: September 18, 2008Inventors: David F. Wiemer, Jeffrey D. Neighbors, John A. Beutler
-
Patent number: 7358377Abstract: Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.Type: GrantFiled: March 29, 2005Date of Patent: April 15, 2008Assignees: University of Iowa Research Foundation, The United States of AmericaInventors: David F. Wiemer, Jeffrey D. Neighbors, John A. Beutler